Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This report suggests that fluvoxamine use may be associated with hair loss, as observed in a 28-year-old male whose condition improved after stopping the drug.

This case report details a 28-year-old male who developed trichotillomania following a traumatic brain injury, highlighting diagnostic challenges in distinguishing overlapping psychiatric and compulsive behaviors, and underscores the importance of a comprehensive, multidisciplinary treatment approach.

This article lists the clinically important interactions and skin reactions of several drugs and substances, including THA, FK506, tamoxifen, tamsulosin, tartrazine, tea tree oil, temazepam, and temozolomide, but provides no new clinical results.

This review concluded that monoclonal antibodies are currently the most effective treatment for COVID-19, with potential efficacy of high-titer convalescent plasma when used early, while multiple other drugs require further evaluation to determine their effectiveness.

This review summarizes 25 small molecule drugs with in vitro and in vivo data for COVID-19 treatment, highlighting their structural diversity and potential to guide future antiviral discovery.

This study found that bupropion was associated with a higher risk of hair loss compared to other antidepressants, with paroxetine presenting the lowest risk.

This study found that fluoxetine did not demonstrate short-term efficacy in treating trichotillomania in a placebo-controlled, double-blind crossover setting.

Keith Kaufman reported promising results on treating male-pattern baldness with oral finasteride at the World Congress of Dermatology.

This study suggests that a newly discovered protein, AMY117, found in Alzheimer's disease brain lesions may be crucial in the disease's development and progression.

A new protein linked to Alzheimer's was discovered, and a hair loss treatment showed effectiveness but had some sexual side effects.

This abstract reports preliminary data on the antidepressant reboxetine, noted for its different mode of action, discussed at a major psychiatry conference; it provides no new research findings.

This case study documents a potential relationship between venlafaxine use and the onset of paranoia, which resolved upon discontinuation and recurred when reintroduced.

This review discusses the neurobiology of sexual function and reports no new results; the authors cover multiple endocrine and neurotransmitter influences on sexual desire, arousal, and orgasm stages.

This article outlines the rationale and design of the Rotterdam Study, summarizes its major findings, and updates its objectives and methods; it reports no new research results.

This review discusses persistent adverse effects of 5α‐reductase inhibitors, like diminished libido and erectile dysfunction, in some patients and highlights the need for patient discussions before therapy, especially for androgenetic alopecia.

This review provides a comprehensive overview of melatonin's physiological roles, effects, and clinical implications, but it does not present new experimental findings.

This review summarizes proposed pathophysiological mechanisms of postpartum depression, highlighting neuroendocrine and neurobiological changes, but reports no new findings and calls for integrated understanding of the disorder.

This review explores finasteride's effects on neuroactive steroid levels and their potential influence on disorders like depression and alcohol withdrawal but reports no new clinical findings.

This review discusses recent strategies targeting the neuroactive steroid biosynthetic pathway to enhance neurosteroidogenesis, highlighting their potential benefits for neurodegenerative and neuropsychiatric diseases, but reports no new clinical findings.

In this study, high-dose dutasteride significantly reduced several core symptoms of PMDD compared to placebo, supporting the role of neurosteroids in this condition.

This preliminary study suggests that finasteride might cause depressive symptoms, indicating the need for cautious prescription in patients at high risk for depression.

In this study, older men using 5α-reductase inhibitors for prostatic enlargement did not show increased risk of suicide, but had elevated risks of self-harm and depression.

This study found that inhibiting neurosteroidogenesis affected GABA A receptor-mediated synaptic inhibition in immature rats but not in adults, suggesting age-dependent modulation of synaptic strength in the spinal dorsal horn.

This review discusses the clinical features of trichotillomania and the challenges in its diagnosis and treatment, reporting no new clinical findings while highlighting the need for specialized therapy and better therapeutic options.

This review discusses the adverse effects of 5α-reductase inhibitors, finasteride and dutasteride, on sexual, psychological, and vascular health, emphasizing the need for physicians to inform patients of these risks.

This study observed that androgenic alopecia patients taking finasteride had altered neuroactive steroid levels and persistent depression symptoms even after stopping the treatment.

This review discusses the potential role of steroid 5α-reductase inhibitors in treating neuropsychiatric disorders related to dopaminergic hyperreactivity but reports no new clinical results.

This article reviews the association between psychopharmaceuticals and medication-induced alopecia, noting that hair regrowth typically occurs after discontinuing or reducing the medication, while mineral supplements' effectiveness remains unclear.

This study reports that men with androgenic alopecia experience altered neuroactive steroid levels associated with persistent depression symptoms even after stopping finasteride treatment.

This study suggests that cerebrospinal fluid levels of the neurosteroids allopregnanolone and pregnanolone correlate negatively with PTSD and negative mood symptoms, with potential sex-specific differences in synthesis enzyme blocks.